DISLIPIDEMIAS
description
Transcript of DISLIPIDEMIAS
![Page 1: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/1.jpg)
![Page 2: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/2.jpg)
Arterial Plaque and
Thrombus Formation by Neville Woolf and Michael J. Davies
![Page 3: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/3.jpg)
![Page 4: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/4.jpg)
![Page 5: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/5.jpg)
![Page 6: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/6.jpg)
![Page 7: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/7.jpg)
![Page 8: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/8.jpg)
MAYO 2002
![Page 9: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/9.jpg)
MAYO 2002
![Page 10: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/10.jpg)
![Page 11: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/11.jpg)
![Page 12: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/12.jpg)
![Page 13: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/13.jpg)
![Page 14: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/14.jpg)
![Page 15: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/15.jpg)
![Page 16: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/16.jpg)
![Page 17: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/17.jpg)
![Page 18: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/18.jpg)
![Page 19: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/19.jpg)
![Page 20: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/20.jpg)
![Page 21: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/21.jpg)
![Page 22: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/22.jpg)
![Page 23: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/23.jpg)
![Page 24: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/24.jpg)
![Page 25: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/25.jpg)
![Page 26: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/26.jpg)
![Page 27: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/27.jpg)
![Page 28: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/28.jpg)
![Page 29: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/29.jpg)
![Page 30: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/30.jpg)
![Page 31: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/31.jpg)
![Page 32: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/32.jpg)
![Page 33: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/33.jpg)
![Page 34: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/34.jpg)
![Page 35: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/35.jpg)
![Page 36: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/36.jpg)
![Page 37: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/37.jpg)
Treatment goals for adults with CMR and lipoprotein
abnormalities.
By definition, patients with CMR have high lifetime risk for CVD. Among patients with CMR and lipoprotein abnormalities, there are patients whom we define as at highest risk for CVD over the short or intermediate term:
those with known clinical CVD and those who do not have clinical CVD but who have diabetes and one or more other CMR factors beyond their dyslipidemia. We recommend that these highest-risk individuals be treated to an LDL cholesterol goal 70 mg/dl, a non-HDL cholesterol goal 100 mg/dl, and an apoB goal 80 mg/dl.
![Page 38: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/38.jpg)
Among patients with CMR and lipoprotein
abnormalities, there are patients whom we define as high (but not highest) risk over the short or intermediate term: those without diabetes or clinical CVD but with two or more major CVD risk factors such as smoking, hypertension, and family history of premature CAD and those with diabetes but no other CMR risk factors. We recommend that these high-risk individuals be treated to an LDL cholesterol goal 100 mg/dl, a non-HDL cholesterol goal 130 mg/dl, and an apoB goal 90 mg/dl.
![Page 39: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/39.jpg)
A statin is the initial drug of choice for the vast majority of people with CMR who have elevated triglycerides and low HDL cholesterol. In individuals on statin therapy who continue to have low HDL cholesterol or elevated non-HDL cholesterol, especially if apoB levels remain elevated, combination therapy is recommended. The preferred agent to use in combination with a statin is nicotinic acid because there is somewhat better evidence for reduction in CVD events with niacin, as monotherapy or in combination, than there is for fibrates.
![Page 40: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/40.jpg)
![Page 41: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/41.jpg)
![Page 42: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/42.jpg)
![Page 43: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/43.jpg)
![Page 44: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/44.jpg)
![Page 45: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/45.jpg)
![Page 46: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/46.jpg)
![Page 47: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/47.jpg)
![Page 48: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/48.jpg)
![Page 49: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/49.jpg)
![Page 50: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/50.jpg)
![Page 51: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/51.jpg)
![Page 52: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/52.jpg)
![Page 53: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/53.jpg)
![Page 54: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/54.jpg)
![Page 55: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/55.jpg)
![Page 56: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/56.jpg)
![Page 57: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/57.jpg)
![Page 58: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/58.jpg)
![Page 59: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/59.jpg)
![Page 60: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/60.jpg)
![Page 61: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/61.jpg)
![Page 62: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/62.jpg)
![Page 63: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/63.jpg)
Adult Treatment Panel III
(ATP III) Guidelines
National Cholesterol Education
Program
![Page 64: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/64.jpg)
5
New Features of ATP III
Focus on Multiple Risk Factors
• Diabetes: CHD risk equivalent
• Framingham projections of 10-year CHD risk
– Identify certain patients with multiple risk
factors for more intensive treatment
• Multiple metabolic risk factors (metabolic
syndrome)
– Intensified therapeutic lifestyle changes
![Page 65: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/65.jpg)
17
Diabetes
In ATP III, diabetes is regarded
as a CHD risk equivalent.
![Page 66: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/66.jpg)
![Page 67: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/67.jpg)
![Page 68: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/68.jpg)
Time, September 4,
2000 Newsweek, September 4,
2000
![Page 69: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/69.jpg)
Number of persons
<5,000
5,000–74,000
75,000–349,000
350,000–1,500,000
>1,500,000
No data available
Prevalence of diabetes in 1997
Adapted from World Health Organization. The World Health Report: life in the 21st century, a vision for all. Geneva: WHO,
1998.
Total cases = 300 million adults
Prevalence of diabetes in 2025 (projected)
![Page 70: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/70.jpg)
![Page 71: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/71.jpg)
Diabetes: A Global Problem Estimated number of people with
type 2 diabetes worldwide
118
151
221
0
50
100
150
200
250
1997 2000 2010
Year
Peo
ple
wit
h d
iab
ete
s
(milli
on
s)
Amos AF, McCarty DJ, Zimmet P. Diabetic Med 1997;14(Suppl 5):S7.
![Page 72: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/72.jpg)
![Page 73: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/73.jpg)
![Page 74: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/74.jpg)
![Page 75: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/75.jpg)
![Page 76: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/76.jpg)
![Page 77: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/77.jpg)
![Page 78: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/78.jpg)
![Page 79: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/79.jpg)
![Page 80: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/80.jpg)
![Page 81: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/81.jpg)
![Page 82: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/82.jpg)
![Page 83: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/83.jpg)
![Page 84: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/84.jpg)
![Page 85: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/85.jpg)
![Page 86: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/86.jpg)
![Page 87: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/87.jpg)
![Page 88: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/88.jpg)
![Page 89: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/89.jpg)
![Page 90: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/90.jpg)
![Page 91: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/91.jpg)
![Page 92: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/92.jpg)
![Page 93: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/93.jpg)
![Page 94: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/94.jpg)
![Page 95: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/95.jpg)
![Page 96: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/96.jpg)
![Page 97: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/97.jpg)
![Page 98: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/98.jpg)
![Page 99: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/99.jpg)
![Page 100: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/100.jpg)
![Page 101: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/101.jpg)
![Page 102: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/102.jpg)
![Page 103: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/103.jpg)
![Page 104: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/104.jpg)
![Page 105: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/105.jpg)
![Page 106: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/106.jpg)
![Page 107: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/107.jpg)
![Page 108: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/108.jpg)
![Page 109: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/109.jpg)
![Page 110: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/110.jpg)
![Page 111: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/111.jpg)
![Page 112: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/112.jpg)
![Page 113: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/113.jpg)
![Page 114: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/114.jpg)
![Page 115: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/115.jpg)
![Page 116: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/116.jpg)
![Page 117: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/117.jpg)
![Page 118: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/118.jpg)
![Page 119: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/119.jpg)
![Page 120: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/120.jpg)
![Page 121: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/121.jpg)
![Page 122: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/122.jpg)
![Page 123: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/123.jpg)
![Page 124: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/124.jpg)
![Page 125: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/125.jpg)
![Page 126: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/126.jpg)
![Page 127: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/127.jpg)
![Page 128: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/128.jpg)
![Page 129: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/129.jpg)
![Page 130: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/130.jpg)
![Page 131: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/131.jpg)
![Page 132: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/132.jpg)
![Page 133: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/133.jpg)
![Page 134: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/134.jpg)
![Page 135: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/135.jpg)
![Page 136: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/136.jpg)
![Page 137: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/137.jpg)
![Page 138: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/138.jpg)
![Page 139: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/139.jpg)
![Page 140: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/140.jpg)
![Page 141: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/141.jpg)
![Page 142: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/142.jpg)
![Page 143: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/143.jpg)
![Page 144: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/144.jpg)
![Page 145: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/145.jpg)
![Page 146: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/146.jpg)
![Page 147: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/147.jpg)
![Page 148: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/148.jpg)
![Page 149: DISLIPIDEMIAS](https://reader035.fdocuments.in/reader035/viewer/2022070505/568c527e1a28ab4916b6eb14/html5/thumbnails/149.jpg)